Biogen's Alzheimer's drug is unlikely to win E.U. approval.
Briefly

The drug maker Biogen said on Wednesday that a panel of drug reviewers in the European Union had indicated that its new Alzheimer's drug was unlikely to be approved there, the latest setback for a medication that has been mired in controversy since it was in approved in the United States in June.
Read at Nytimes
[
add
]
[
|
|
]
more Europe news Briefly
[ Load more ]